All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Legend Biotech, Pfizer, Roche, and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View multiple myeloma content recommended for you
The role of MRD as an endpoint in clinical trials for MM
Do you know... In multiple myeloma clinical trials, what is a potential advantage of MRD as a surrogate endpoint compared with traditional endpoints such as OS or PFS?
Advances in the treatment of multiple myeloma have resulted in deeper and more durable responses in clinical trials, with corresponding improvements in progression-free and overall survival.1 While these developments reflect important progress, they have also extended the time required for traditional clinical trial endpoints to mature.1 This has led to increased interest in alternative endpoints that may enable earlier and more sensitive assessment of treatment effects.1
Measurable residual disease (MRD), detected using highly sensitive techniques such as next-generation flow cytometry (NGF) or next-generation sequencing (NGS), has emerged as a potential tool to evaluate depth of response earlier.2 Clinical trial data have demonstrated an association between MRD status and long-term outcomes, supporting ongoing evaluation of MRD as a surrogate clinical trial endpoint in multiple myeloma, potentially accelerating regulatory decision-making.1,3
This educational resource is independently supported by Bristol Myers Squibb. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.
References